المؤلفون: E. V. Glazkova, M. A. Frolova, E. R. Israelyan, Е. В. Глазкова, М. А. Фролова, Э. Р. Исраелян

المصدر: Meditsinskiy sovet = Medical Council; № 9 (2022); 201-206 ; Медицинский Совет; № 9 (2022); 201-206 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: токсичность, chemotherapy, ixabepilone, capecitabine, pleurodesis, toxicity, химиотерапия, иксабепилон, капецитабин, плевродез

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6934/6231; Dent R., Hanna W.M., Trudeau M., Rawlinson E., Sun P., Narod S.A. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2009;115(2):423-428. https://doi.org/10.1007/s10549-008-0086-2.; Lu Y.-S., Im S.-A., Colleoni M., Franke F., Bardia A., Cardoso F. et al. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR + /HER2 -Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clin Cancer Res. 2022:28(5):851-859. https://doi.org/10.1158/1078-0432.CCR-21-3032.; Schmid P., Adams S., Rugo H.S., Schneeweiss A., Barrios C.H., Iwata H. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379(22):2108-2121. https://doi.org/10.1056/NEJMoa1809615.; Miles D., Gligorov J., Andre F., Cameron D., Schneeweiss A., Barrios C. et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021;32(8):994-1004. https://doi.org/10.1016/j.annonc.2021.05.801.; Cortes J., Cescon D.W., Rugo H.S., Nowecki Z., Im S.-A., Yusof M.M. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triplenegative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817-1828. https://doi.org/10.1016/S0140-6736(20)32531-9.; Cardoso F., Paluch-Shimon S., Senkus E., Curigliano G., Aapro M.S., Andre F. et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623-1649. https://doi.org/10.1016/j.annonc.2020.09.010.; Kaufman P.A., Awada A., Twelves C., Yelle L., Perez E.A., Velikova G. et al. Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. J Clin Oncol. 2015;33(6):594-601. https://doi.org/10.1200/JCO.2013.52.4892.; Tutt A., Tovey H., Cheang M.C.U., Kernaghan S., Kilburn L., Gazinska P. et al. A randomised phase III trial of carboplatin compared with docetaxel in BRCA1/2 mutated and pre-specified triple negative breast cancer “BRCAness” subgroups: the TNT Trial. Nat Med. 2018;24(5):628-637. https://doi.org/10.1038/s41591-018-0009-7.; Robson M.E., Tung N., Conte P., Im S.-A., Senkus E., Xu B. et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558-566. https://doi.org/10.1093/annonc/mdz012.; Litton J.K., Hurvitz S.A., Mina L.A., Rugo H.S., Lee K.-H., Goncalves A. et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31(11):1526-1535. https://doi.org/10.1016/j.annonc.2020.08.2098.; Perez E.A., Lerzo G., Pivot X., Thomas E., Vahdat L., Bosserman L. et al. Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine. J Clin Oncol. 2007;25(23):3407-3414. https://doi.org/10.1200/JCO.2006.09.3849.; Thomas E.S., Gomez H.L., Li R.K., Chung H.-C., Fein L.E., Chan V.F. et al. Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment. J Clin Oncol. 2007;25(33):5210-5217. https://doi.org/10.1200/JCO.2007.12.6557.; Rugo H.S., Roche H., Thomas E., Chung H.C., Lerzo G.L., Vasyutin I. et al. Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials. Clin Breast Cancer. 2018;18(6):489-497. https://doi.org/10.1016/j.clbc.2018.07.024.; Vahdat L.T., Thomas E.S., Roche H.H., Hortobagyi G.N., Sparano J.A., Yelle L. et al. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Support Care Cancer. 2012;20(11):2661-2668. https://doi.org/10.1007/s00520-012-1384-0.; Valero V., Vrdoljak E., Xu B., Thomas E., Gomez H., Manikhas A. et al. Maintenance of Clinical Efficacy After Dose Reduction of Ixabepilone Plus Capecitabine in Patients With Anthracycline- and Taxane-Resistant Metastatic Breast Cancer: A Retrospective Analysis of Pooled Data From 2 Phase III Randomized Clinical Trials. Clin Breast Cancer. 2012;12(4):240-246. https://doi.org/10.1016/j.clbc.2012.03.013.; Kassam F., Enright K., Dent R., Dranitsaris G., Myers J., Flynn C. et al. Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design. Clin Breast Cancer. 2009;9(1):29-33. https://doi.org/10.3816/CBC.2009.n.005.; Sasaki T., Yasuda H., Nakayama K., Okinaga S., Suzuki T., Asada M. et al. A randomized phase II trial comparing carboplatin pleurodesis with cisplatin pleurodesis in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) with malignant pleural effusions (MPE). J Clin Oncol. 2006;24(18_Suppl):17012-17012. https://doi.org/10.1200/jco.2006.24.18_suppl.17012.; Bakr R.M., El-Mahalawy I.I., Abdel-Aal G.A., Mabrouk A.A., Ali A.A. Pleurodesis using different agents in malignant pleural effusion. Egypt J Chest Dis Tuber. 2012;61(4):399-404. https://doi.org/10.1016/j.ejcdt.2012.07.005.; Badrawy M.K.E., Ali R.E.-M., Hewidy A.A., El-Layeh M.A., Akl F.M.F., Shebl A. Efficacy and safety of intrapleural cisplatin versus silver nitrate in treatment of malignant pleural effusion. Egypt J Brochol. 2018;(12):98-104. Available at: https://ejb.springeropen.com/articles/10.4103/ejb.ejb_39_17.; Lee J.J., Swain S.M. Peripheral Neuropathy Induced by MicrotubuleStabilizing Agents. J Clin Oncol. 2006;24(10):1633-1642. https://doi.org/10.1200/JCO.2005.04.0543.; https://www.med-sovet.pro/jour/article/view/6934

الاتاحة: https://www.med-sovet.pro/jour/article/view/6934
https://doi.org/10.21518/2079-701X-2022-16-9-201-206

المؤلفون: D. A. Ivanov, I. N. Dyakov, S. K. Zyryanov, Д. А. Иванов, И. Н. Дьяков, С. К. Зырянов

المصدر: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 14, No 2 (2021); 103–114 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 14, No 2 (2021); 103–114 ; 2070-4933 ; 2070-4909

مصطلحات موضوعية: экономический эффект, chemotherapy, non-small cell lung cancer, breast cancer, vinorelbine, pemetrexed, ixabepilone, economic benefit, химиотерапия, немелкоклеточный рак легкого, рак молочной железы, винорелбин, пеметрексед, иксабепилон

وصف الملف: application/pdf

Relation: https://www.pharmacoeconomics.ru/jour/article/view/519/366; Каприн А.Д., Старинский В.В., Шахзадова А.О. (ред.) Состояние онкологической помощи населению России в 2019 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» МЗ РФ; 2020.; Рак молочной железы. Клинические рекомендации МЗ РФ; 2018. URL: https://legalacts.ru/doc/klinicheskie-rekomendatsii-rakmolochnoi-zhelezy-utv-minzdravom-rossii/ (дата обращения 20.05.2021).; Рак молочной железы. Клинические рекомендации МЗ РФ; 2021. URL: https://cr.minzdrav.gov.ru/schema/379_4 (дата обращения 20.05.2021).; Злокачественное новообразование бронхов и легкого. Клинические рекомендации МЗ РФ. URL: https://cr.minzdrav.gov.ru/recomend/30_1 (дата обращения 20.05.2021).; Рудакова А.В. Проценко С.А. Назначение перорального винорелбина при немелкоклеточном раке легкого: клинические и фармакоэкономические аспекты. Вопросы онкологии. 2016, 62 (6): 812–6.; Шабалкин П.И. Анализ влияния на бюджет Российской Федерации применения перорального винорелбина для лечения метастатического рака молочной железы. Фарматека. 2018, 7: 71–5.; Bennouna J., Havel L., Krzakowski M., et al. Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: Final results of an international randomized phase II study (NAVotrial 01). Clin. Lung Cancer. 2014; 15 (4): 258–65. https://doi.org/10.1016/j.cllc.2014.04.007.; Практические рекомендации по лечению злокачественных опухолей Российского общества клинической онкологии. URL: https://rosoncoweb.ru/standarts/RUSSCO/ (дата обращения 20.05.2021).; Государственный реестр лекарственных средств. URL: https:// grls.rosminzdrav.ru/GRLS.aspx (дата обращения 20.05.2021).; Методические рекомендации по оценке сравнительной клинической эффективности и безопасности лекарственного препарата. Центр экспертизы и контроля качества медицинской помощи Минздрава России. М.; 2016.; Государственный реестр предельных отпускных цен. URL: https://grls.rosminzdrav.ru/pricelims.aspx (дата обращения 20.05.2021).; ФАС России. Предельные размеры оптовых надбавок и предельные размеры розничных надбавок к ценам на жизненно необходимые и важнейшие лекарственные препараты, установленные в субъектах Российской Федерации (данные по состоянию на 21.10.2020 г.). URL: https://fas.gov.ru/documents/b-n-5d7183c4-9786-4fc1-9d30-3f3453513bc0 (дата обращения 20.05.2021).; Методические рекомендации Центра экспертизы и контроля качества медицинской помощи. URL: https://rosmedex.ru/hta/recom/ (дата обращения 20.05.2021).; PDQ Adult Treatment Editorial Board Non-Small Cell Lung Cancer Treatment (PDQ®): Health Professional Version. National Cancer Institute (US); 2002.; Goffin J., Lacchetti C., Ellis P.M., et al. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol. 2010; 5 (2): 260–74. https://doi.org/10.1097/JTO.0b013e3181c6f035.; Hernandez-Aya L.F., Ma C.X. Chemotherapy principles of managing stage IV breast cancer in the United States. Chin Clin Oncol. 2016; 5 (3): 42. https://doi.org/10.21037/cco.2016.04.01.; Rivera E. Management of metastatic breast cancer: Monotherapy options for patients resistant to anthracyclines and taxanes. Am J Clin Oncol. 2010; 33 (2): 176–85. https://doi.org/10.1097/COC.0b013e3181931049.; Caparica R., Lambertini M., De Azambuja E. How I treat metastatic triple-negative breast cancer. ESMO Open. 2019; 4 (Suppl. 2): e000504. https://doi.org/10.1136/esmoopen-2019-000504.; Jerusalem G., Rorive A., Collignon J. Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer. Futur Oncol. 2015; 11 (12): 1775–89. https://doi.org/10.2217/fon.15.80.; Partridge A.H., Rumble R.B., Carey L.A., et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2014; 32 (29): 3307–29. https://doi.org/10.1200/JCO.2014.56.7479.; https://www.pharmacoeconomics.ru/jour/article/view/519

الاتاحة: https://www.pharmacoeconomics.ru/jour/article/view/519
https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.088

المؤلفون: A. Mescheryakov A., E. Lubennikova V., M. Abramov E., А. Мещеряков А., Е. Лубенникова В., М. Абрамов Е.

المصدر: Meditsinskiy sovet = Medical Council; № 19 (2018); 62-66 ; Медицинский Совет; № 19 (2018); 62-66 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2018-19

مصطلحات موضوعية: Ixabepilone, triply negative breast cancer, chemotherapy, epothilones, βIII-tubulin, иксабепилон, трижды негативный рак молочной железы, химиотерапия, эпотилоны, βIII-тубулин

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/2748/2700; Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol., 2009, 27: 1160-1167.; Rugo HS et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). Journal of Clinical Oncology, 2015, 33(21): 2361.; Cooper GM, Ganem D. The Cell: A Molecular Approach. Nature Medicine, 1997, 3(9): 1042-1042.; English DP, Roque DM, Santin АD. Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents? Expert Review OF Anticancer Therapy, 2013, 13(1): 63-74.; Sève P, Dumontet С. Is class III β-tubulin a predictive factor in patients receiving tubulinbinding agents The Lancet Oncology, 2008, 9(2): 168-175.; Dumontet C, Jordan MA, Lee FFY. Ixabepilone: targeting βIII-tubulin expression in taxaneresistant malignancies. Molecular Cancer Therapeutics, 2009, 8(1): 17-25.; Lee FYF et al. Experimental Therapeutics, Preclinical Pharmacology-BMS-247550: A Novel Epothilone Analog with a Mode of Action Similar to Paclitaxel but Possessing Superior Antitumor Efficacy. Clinical Cancer Research, 2001, 7(5): 1429-1437.; Low JA et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. Journal of Clinical Oncology, 2005, 23(12): 2726-2734.; Thomas E. et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. Journal of Clinical Oncology, 2007, 25(23); 3399-3406.; Perez EA et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. Journal of Clinical Oncology, 2007, 25(23): 3407-3414.; Fountzilas G et al. Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial. PloS one, 2013, 8(7): e69256.; Rugo HS et al. A randomized, phase II, threearm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Research and Treatment, 2013, 139(2): 411-419.; Smith JW et al. Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients. Breast Cancer Research and Treatment, 2013, 142(2): 381-388.; Li J, Ren J, Sun W. Systematic review of ixabepilone for treating metastatic breast cancer. Breast Cancer, 2017, 24(2): 171-179.; Официальная инструкция препарата Икземпра в РФ; Thomas ES et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. Journal of Clinical Oncology, 2007, 25(33): 5210-5217.; Sparano JA et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology, 2010, 28(20): 3256-3263.; Fornier М. Ixabepilon plus capecitabin for breast cancer patients with an Early metastatic relapse after adjuvant chemotherapy: two clinical trials. Clinical Breast Cancer, 2010: 352-358.; Rugo HS et al. Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials. Clinical Breast Cancer, 2018.; Valero V., Vrdoljak E., Xu B., et al. Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials. Clin Breast Cancer, 2012 Aug, 12(4): 240-6.; Osborne C. et al. Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer. Clinical breast cancer, 2018, 18(1): e89-e95.; Vahdat LT et al. Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Research and Treatment, 2013, 140(2): 341-351.; Baselga J et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. Journal of Clinical Oncology, 2008, 27(4): 526-534.; Saura C et al. Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker. The Oncologist, 2013, 18(7): 787-794.; Yardley DA et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer. Breast Cancer Research and Treatment, 2017, 164(3): 649-658.; Campone M et al. UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer. European Journal of Cancer, 2018, 103: 184-194.; https://www.med-sovet.pro/jour/article/view/2748

الاتاحة: https://www.med-sovet.pro/jour/article/view/2748
https://doi.org/10.21518/2079-701X-2018-19-62-66

المؤلفون: T. SEMIGLAZOVA Y., V. KLYUGE A., E. KOROBEYNIKOVA A., P. KRIVOROTKO V., R. PALTUEV M., G. TELETAEVA M., D. LATIPOVA H., V. KLIMENKO V., E. TACHENKO V., A. Novik V., A. SEMENOVA I., V. SEMIGLAZOV V., S. PROTSENKO A., V. SEMIGLAZOV F., Т. СЕМИГЛАЗОВА Ю., В. КЛЮГЕ А., Е. КОРОБЕЙНИКОВА А., П. КРИВОРОТЬКО В., Р. ПАЛТУЕВ М., Г. ТЕЛЕТАЕВА М., Д. ЛАТИПОВА Х., В. КЛИМЕНКО В., Е. ТКАЧЕНКО В., А. НОВИК В., А. СЕМЕНОВА И., В. СЕМИГЛАЗОВ В., С. ПРОЦЕНКО А., В. СЕМИГЛАЗОВ Ф.

المصدر: Meditsinskiy sovet = Medical Council; № 6 (2017); 72-83 ; Медицинский Совет; № 6 (2017); 72-83 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2017-6

مصطلحات موضوعية: Ixabepilone, breast cancer, neoadjuvant chemotherapy, pCR, progression-free survival, overall survival, quality of life, triple negative subtype, intensively «treated» breast cancer, иксабепилон, рак молочной железы, неоадъювантная терапия, выживаемость без прогрессирования, общая выживаемость, качество жизни, трижды негативный подтип, интенсивно «предлеченный» РМЖ

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/1889/1828; Desantis C, Siegel R, Bandi P, and Jamal А. Breast cancer statistics 2011. CA: A Cancer Journal for Clinicians, 2011, 61(6): 408–418.; Семиглазов В.Ф., Палтуев Р.М., Семиглазова Т.Ю. и др. Опухоли репродуктивной системы. М.: Рекламно-издательская группа МегаПро, 2013. / Semiglazov VF, Paltuev RM, Semiglazova TY., et al. Tumors of reproductive system. M.: Advertising and Publishing Group MegaPro, 2013.; Семиглазов В.Ф., Семиглазов В.В., Криворотько П.В., Палтуев Р.М., Дашян Г.А., Семиглазова Т.Ю. Руководство по лечению рака молочной железы. 2016, 155с. / Semiglazov VF, Semiglazov VV, Krivorotko PV, Paltuev RM, Dashyan GA, Semiglazova TY. Guide to treatment of breast cancer. 2016, 155.; Семиглазов В.В., Жабина А.С., Осипов М.А., Котова З.С. Клименко В.В. и соавт. Качество жизни – принципиальный критерий эффективности таргетной терапии метастатического HER2-положительного рака молочной железы. Современная онкология, 2015, 17(1): 19-24./ Semiglazov VV, Zhabina AS, Osipov MA, Kotova Z.S., Klimenko V.V. Et al. Quality of life is a criterion of the effectiveness of targeted therapy for metastatic HER2-positive breast cancer. Modern Oncology, 2015, 17(1): 19-24.; Семиглазова Т.Ю., Гершанович М.Л. Пероральные фторпиримидины в химиотерапии злокачественных опухолей. Вопр. онкологии, 2001, 47(4): 388-394. / Semiglazova TY, Gershanovich ML. Peroral fluoropyrimidines in chemical therapy of malignant tumours. Vopr onkologii, 2001, 47(4): 388-394.; Семиглазова Т.Ю., Гершанович М.Л. Кселода (капецитабин) в лечении диссеминированного рака молочной железы после исчерпанного эффекта антрациклинов и таксанов. Вопр. онкологии, 2001, 47(3): 298-302./Semiglazova TY, Gershanovich ML. Xeloda (capecitabine) in therapy of disseminated mammary gland cancer after the exhausted effect of antracyclines and taxanes. Vopr onkologii, 2001, 47(3): 298- 302.; Semiglazova T, Gershanovich M. The efficacy of Capecitabine (Xeloda) in Antracyclin- refractory and Antracyclin and Docetaxel-refractory metastatic breast cancer (MBC). Proc Am Soc Clin Oncol, 2002, 21(2061): 164.; Семиглазова Т.Ю., Клюге В.А., Семиглазов В.В., Криворотько П.В., Дашян Г.А., Палтуев Р.М., Ткаченко Е.В., Донских Р.В., Семиглазов В.Ф. Новые возможности улучшения продолжительности и качества жизни: эрибулин в лечении больных диссеминированным раком молочной железы. Современная онкология, 2016, 18(2): 29-35./ Semiglazova TY, Klyuge VA, Semiglazov VV, Krivorotko PV, Dashyan GA, Paltuev RM, Tkachenko EV, Donskikh RV, Semiglazov VF. New possibilities for improving the duration and quality of life: Erybulin in the treatment of patients with disseminated breast cancer. Modern oncology, 2016, 18(2): 29-35.; Guarneriand V, Conte P. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist, 2009, 14(7): 645–656.; Perou CM, Sørile T, Eisen MB et al. Molecular portraits of human breast tumours. Nature, 2000, 406(6797): 747-752.; Fojo AT and Menefee M. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Seminars in Oncology, 2005, 32(7): S3–S8.; Geney R, Ungureanu IM, Li D, and Ojima I. Overcoming multidrug resistance in taxane chemotherapy. Clinical Chemistry and Laboratory Medicine, 2002, 40(9): 918–925.; Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annual Review of Medicine, 1997, 48: 353-374.; Hudis CA and Gianni L. Triple-negative breast cancer: an unmet medical need. The oncologist, 2011, 16 (1): 1–11.; Orr GA, Verdier-Pinard P, McDaid H, and Horwitz SB. Mechanisms of Taxol resistance related to microtubules, Oncogene, 2003, 22(47): 7280–7295.; Hari M, Yang H, Zeng C, Canizales M, and Cabral F. Expression of class III β-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motility and the Cytoskeleton, 2003, 56(1): 45–56.; Shalli K, Brown I, Heys SD and Schofield AC. Alterations of β-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB Journal, 2005, 19(10): 1299–1301.; Tommasi S, Mangia A, Lacalamitaetal R. Cytoskeletonand paclitaxel sensitivity in breast cancer: the role of β-tubulins. International Journal of Cancer, 2007, 120(10): 2078-2085.; Alli E, Sharma VB, Sunderesakumar P, and Ford JM. Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADPribose) polymerase. Cancer Research, 2009, 69(8): 3589-3596.; Rottenberg S, Jaspers JE, Kersbergen A et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105(44): 17079-17084.; Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 2005, 434(7035): 913-917.; Farmer H, McCabe H, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 2005, 434(7035):917-921.; O’Shaughnessy J, Osborne C, Pippen JE et al. Iniparib plus chemotherapy in metastatic triple- negative breast cancer. New England Journal of Medicine, 2011, 364(3): 205-214.; O’Shaughnessy J, Schwartzberg LS, Danso MA et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/ carboplatin (G/C) in metastatic triplenegative breast cancer (TNBC). Journal of Clinical Oncology, 2011, 29(15s), abstract 1007.; Cortes J, O’Shaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open- label randomised study. The Lancet, 2011, 377(9769): 914-923.; Bode CJ, Gupta ML, Rei EA, Suprenant KA, Georg GI, and. Himes RH. Epothilone and paclitaxel: unexpect eddierences in promoting the assembly and stabilization of yeast microtubules. Biochemistry, 2002, 41(12): 3870-3874.; Bollag DM, McQueney PA, Zhu J et al. Epothilones, a new class of microtubule- stabilizing agents with a taxol-like mechanism of action. Cancer Research, 1995, 55(11): 2325- 2333.; Giannakakou P, Gussio R, Nogales E et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97(6): 2904–2909.; Chuang E, Wiener N, Christos P et al. Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary. Annals of Oncology, 2010, 21(10): 2075–2080.; Hunt JT. Discovery of Ixabepilone. Molecular Cancer Therapeutics, 2009, 8(2): 275–281.; Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clinical Cancer Research, 2001, 7(5): 1429–1437.; Jordan M, Miller H, Ni L, et al. The Pat-21 breast cancer model derived from a patient with primary taxol resistance recapitulates the phenotype of its origin, has altered betatubulin expression and is sensitive to ixabepilone. in Proceedings of the American Association for Cancer Research Annual Meeting, 2006, abstract LB-280, Washington, DC, USA.; Perez EA, Patel T, and Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2- negative (triple-negative) breast cancer. Breast Cancer Research and Treatment, 2010, 121(2): 261–271.; Lee FY, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemotherapy and Pharmacology, 2009, 63(2): 201–212.; Rivera E, Lee J, and Davies A. Clinical development of ixabepilone and other epothilones in patients with advanced solidtumors. Oncologist, 2008, 13(12): 1207–1223.; Goodin S, Kane MP, and Rubin EH. Epothilones: mechanism of action and biologic activity. Journal of Clinical Oncology, 2004, 22(10): 2015–2025.; Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. Journal of Clinical Oncology, 2007, 25(23): 3407–3414.; Sparano JA, Vrdoljak E, Rixe O, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology, 2010, 28(20): 3256–3263.; Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. Journal of Clinical Oncology, 2007, 25(33): 5210–5217.; Jassem J, Fein L, Karwal M, et al. Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies. Breast, 2012, 21(1): 89– 94.; Rugo HS, Campone M, Amadori D, et al. Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bevacizumab (pac/bev) as first-line therapy for metastatic breast cancer (MBC): final results. Journal of Clinical Oncology, 2010, 28(15s): 1040.; Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New England Journal of Medicine, 2007, 357(26): 2666– 2676.; Smith JW, Vukelja SJ, Rabe AC et al. Final results of a phase II randomized trial of weekly or every-3-week ixabepilone in metastatic breast cancer (MBC). in Proceedings of the Breast Cancer Symposium, 2010, Abstract 268.; Moulder S, Li H, Wang M, et al. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Breast Cancer Research and Treatment, 2010, 119(3): 663–671.; Awada A, Piccart MJ, Jones SF, et al. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy. Cancer Chemotherapy and Pharmacology, 2009, 63(3): 417–425.; Roch´e H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. Journal of Clinical Oncology, 2007, 25(23): 3415–3420.; Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS- 247550), an epothilone B analog, in patients with taxaneresistant metastatic breast cancer. Journal of Clinical Oncology, 2007, 25(23): 3399–3406.; Plummer R, Woll P, Fyfeetal D. A phase I and pharmacokinetic study of lxabepilone in combination with carboplatin in patients with advanced solid malignancies. Clinical Cancer Research, 2008, 14(24): 8288–8294.; Tolaney SM, Najita J, Chen W, et al. A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer. Cancer Research, 2009, 69, abstract 3137.; Baselga J, Zambetti M, Llombart-Cussac A. et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. Journal of Clinical Oncology, 2009, 27(4): 526–534.; Bear HD, Anderson S, Smith RE et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. Journal of Clinical Oncology, 2006, 24(13): 2019–2027.; Wardley A. Capecitabine: expanding options for the treatment of patients with early or locally advanced breast cancer. Oncologist, 2006, 11(1): 20–26.; Wolmark N, Wang J, Mamounas E, Bryant J, and Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nineyear results from National Surgical Adjuvant Breast and Bowel Project B-18. Journal of the National Cancer Institute Monographs, 2001, 30: 96–102.; Rosenberg KJ, Ross JL, Feinstein HE, Feinstein SC, and Israelachvili J. Complementary dimerization of microtubule-associated tau protein: implications for microtubule bundling and taumediated pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105(21): 7445–7450.; Felgner H, Frank R, Biernat J, et al. Domains of neuronal microtubule-associated proteins and flexural rigidity of microtubules. Journal of Cell Biology, 1997, 138(5): 1067– 1075.; Choi MC, Raviv U, Miller HP, et al. Human microtubule associated-protein tau regulates the number of protofilaments in microtubules: a synchrotron X-ray scattering study. Biophysical Journal, 2009, 97(2): 519–527.; Katherine H, Rak Tkaczuk. Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer. Breast Cancer: Basic and Clinical Research, 2011, 5: 1–14.; American Cancer Society. Cancer Facts &Figures 2016. Atlanta: American Cancer Society, 2016.; https://www.med-sovet.pro/jour/article/view/1889

الاتاحة: https://www.med-sovet.pro/jour/article/view/1889
https://doi.org/10.21518/2079-701X-2017-6-72-83

المؤلفون: Иванов Д.А., Дьяков И.Н., Зырянов С.К.

المصدر: Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология

مصطلحات موضوعية: Clinical-economic study, chemotherapy, non-small cell lung cancer, breast cancer, vinorelbine, Pemetrexed, ixabepilone, economic benefit, клинико-экономическое исследование, химиотерапия, немелкоклеточный рак легкого, рак молочной железы, винорелбин, пеметрексед, иксабепилон, экономический эффект

Relation: https://repository.rudn.ru/records/article/record/80734/

الاتاحة: https://repository.rudn.ru/records/article/record/80734/